share_log

UniQure Has Dosed The First Patient In GenTLE Phase 1/2a Trial Of AMT-260 For Refractory Mesial Temporal Lobe Epilepsy

Benzinga ·  Nov 21 07:08
UniQure Has Dosed The First Patient In GenTLE Phase 1/2a Trial Of AMT-260 For Refractory Mesial Temporal Lobe Epilepsy
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment